Listen and follow our podcasts on:

Bayer.

In this podcast, GI oncologists Prof. Tanios Bekaii-Saab and Prof. Shubham Pant discuss how to use data from real-world evidence studies alongside data from clinical trials to optimise the management of patients with metastatic colorectal cancer. 

 

The medical experts review: 

 

  • Recent real-world evidence presented at ASCO GI 2024 from studies in later-line treatment of metastatic colorectal cancer 
  • What is meant by real-world evidence, and the types of information sources included 
  • The challenges and considerations when using real-world evidence 
  • How HCPs can use real-world evidence alongside data from clinical trials to inform patient management 

 

Clinical Takeaways

  • Randomised clinical trials are the gold standard to determine causal effect and help guide clinical practice, but do not represent patients in routine clinical practice 
  • Real-world evidence can augment traditional clinical data by providing useful efficacy and safety information of treatments in patients representative of those in clinical practice 
  • However, we need to be mindful of the limitations and potential biases that might arise from real-world data collection and analysis methods 

Interpreting real-world evidence in later-line mCRC: Educational objectives

  • Understand how real-world evidence can complement data obtained from randomised controlled trials
  • Know the benefits and limitations of real-world evidence
  • Review recent RWE data for mCRC and understand its implications for clinical practice 

Tanios Bekaii-Saab, MD is a Professor of Medicine at the Mayo Clinic College of Medicine and Science. He is the Chair for Hematology and Medical Oncology for the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona, USA. He is the leader of the Gastrointestinal Cancer for the Enterprise-wide Mayo Clinic Cancer Center Dr. Bekaii-Saab is currently the co-leader of the Hepatobiliary Cancer Sub-Committee of the Alliance for Clinical Trials in Oncology and the Co-Chair for the National Cancer Institute’s Hepatobiliary Task Force.

 

Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.


Dr. Bekaii-Saab served as a reviewer for many high impact journals and sits on the editorial board of the prestigious Journal of the National Cancer Institute. Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters, including papers in such journals as New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

Prof. Tanios Bekaii-Saab has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS. Consulting (to institution): Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA and Merck. Consulting (to self): Stemline, AbbVie, Blueprint Medicines , Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine and Sanofi. Glaxo SmithKline , Xilio. IDMC/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan and 1Globe.  Scientific Advisory Board: Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma. Royalties: Uptodate. Inventions/Patents: WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene, WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center. Dr. Pant is recognised as an international expert in GI cancers with an emphasis on pancreatic and biliary cancers and Phase 1 trials.

 

Dr. Pant's research focuses on novel immunotherapeutic approaches and targeted therapies in GI cancers, including devising novel ways to target the KRAS mutation. He has been the lead/co-lead of several global practice-changing studies, including 'Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicenter, single-arm, phase 2b study'; 'Adagrasib in advanced solid tumors harboring a KRASG12C mutation' and 'Erdafitinib in patients with advanced solid tumors with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study'; amongst others. He has over 100 peer-reviewed publications and has published in high-impact journals, including The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He is frequently invited to present his research at national and international meetings. He collaborates on numerous grants, including R01 and SPORE grants funded by the National Institute of Health. Dr. Pant serves on the National Cancer Institute (NCI) Pancreas Task Force and the Pancreatic Cancer Action Network's (PanCan) Scientific and Medical Advisory Board. He also helped draft the American Society of Clinical Oncology (ASCO) Metastatic Pancreatic Cancer Guidelines, which provide evidence-based recommendations for physicians. He is also the editor of the book Pancreatic Cancer: Current Therapeutics and Future Directions (Publisher: Springer).

Prof. Shubham Pant has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Alligator Bioscience, Amal Therapeutics, Arcus, AskGene Pharma, Astellas, AstraZeneca, BioNTech, Boehringer Ingelheim, BPGBio, Bristol-Myers Squibb, Elicio, Framewave, Immuneering, ImmunoMET, Ipsen, Janssen, Jazz, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Nihon Medi-Physics Co, Ltd, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds, Zymeworks

Listen and follow our podcasts on:

Bayer.

In this podcast, GI oncologists Prof. Tanios Bekaii-Saab and Prof. Shubham Pant discuss how to use data from real-world evidence studies alongside data from clinical trials to optimise the management of patients with metastatic colorectal cancer. 

 

The medical experts review: 

 

  • Recent real-world evidence presented at ASCO GI 2024 from studies in later-line treatment of metastatic colorectal cancer 
  • What is meant by real-world evidence, and the types of information sources included 
  • The challenges and considerations when using real-world evidence 
  • How HCPs can use real-world evidence alongside data from clinical trials to inform patient management 

 

Clinical Takeaways

  • Randomised clinical trials are the gold standard to determine causal effect and help guide clinical practice, but do not represent patients in routine clinical practice 
  • Real-world evidence can augment traditional clinical data by providing useful efficacy and safety information of treatments in patients representative of those in clinical practice 
  • However, we need to be mindful of the limitations and potential biases that might arise from real-world data collection and analysis methods 

Interpreting real-world evidence in later-line mCRC: Educational objectives

  • Understand how real-world evidence can complement data obtained from randomised controlled trials
  • Know the benefits and limitations of real-world evidence
  • Review recent RWE data for mCRC and understand its implications for clinical practice 

Tanios Bekaii-Saab, MD is a Professor of Medicine at the Mayo Clinic College of Medicine and Science. He is the Chair for Hematology and Medical Oncology for the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona, USA. He is the leader of the Gastrointestinal Cancer for the Enterprise-wide Mayo Clinic Cancer Center Dr. Bekaii-Saab is currently the co-leader of the Hepatobiliary Cancer Sub-Committee of the Alliance for Clinical Trials in Oncology and the Co-Chair for the National Cancer Institute’s Hepatobiliary Task Force.

 

Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.


Dr. Bekaii-Saab served as a reviewer for many high impact journals and sits on the editorial board of the prestigious Journal of the National Cancer Institute. Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters, including papers in such journals as New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

Prof. Tanios Bekaii-Saab has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS. Consulting (to institution): Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA and Merck. Consulting (to self): Stemline, AbbVie, Blueprint Medicines , Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine and Sanofi. Glaxo SmithKline , Xilio. IDMC/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan and 1Globe.  Scientific Advisory Board: Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma. Royalties: Uptodate. Inventions/Patents: WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene, WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center. Dr. Pant is recognised as an international expert in GI cancers with an emphasis on pancreatic and biliary cancers and Phase 1 trials.

 

Dr. Pant's research focuses on novel immunotherapeutic approaches and targeted therapies in GI cancers, including devising novel ways to target the KRAS mutation. He has been the lead/co-lead of several global practice-changing studies, including 'Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicenter, single-arm, phase 2b study'; 'Adagrasib in advanced solid tumors harboring a KRASG12C mutation' and 'Erdafitinib in patients with advanced solid tumors with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study'; amongst others. He has over 100 peer-reviewed publications and has published in high-impact journals, including The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He is frequently invited to present his research at national and international meetings. He collaborates on numerous grants, including R01 and SPORE grants funded by the National Institute of Health. Dr. Pant serves on the National Cancer Institute (NCI) Pancreas Task Force and the Pancreatic Cancer Action Network's (PanCan) Scientific and Medical Advisory Board. He also helped draft the American Society of Clinical Oncology (ASCO) Metastatic Pancreatic Cancer Guidelines, which provide evidence-based recommendations for physicians. He is also the editor of the book Pancreatic Cancer: Current Therapeutics and Future Directions (Publisher: Springer).

Prof. Shubham Pant has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Alligator Bioscience, Amal Therapeutics, Arcus, AskGene Pharma, Astellas, AstraZeneca, BioNTech, Boehringer Ingelheim, BPGBio, Bristol-Myers Squibb, Elicio, Framewave, Immuneering, ImmunoMET, Ipsen, Janssen, Jazz, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Nihon Medi-Physics Co, Ltd, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds, Zymeworks

Programme summary
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ASCO 2025

Coming Soon: Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Dr Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock 1 MIN
  • calendar May 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA